Cerecor Inc.'s chief medical officer (CMO), Ronald Marcus, acknowledging that upbeat phase III data from Alkermes plc in major depressive disorder (MDD) whetted appetites for his firm's pair of earlier-stage candidates, told BioWorld Today that tweaks in trial design can "dramatically improve your probability of success," as Alkermes showed and Cerecor may, too.